Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$15.91 +2.63%

+$0.41 today

Market cap
$3.52B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 1.88M

Average 3.70M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$235.46M

FY 2025 · Annual

Investing Cash Flow

$192.80M

FY 2025 · Annual

Financing Cash Flow

$1.60M

FY 2025 · Annual

-99.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
Deferred Income Tax00000
Stock-Based Compensation48.45M56.14M86.03M94.14M62.42M
Change in Working Capital97.34M11.25M(32.46M)14.62M(23.31M)
Accounts Receivables77.79M97K5.22M00
Inventory00000
Accounts Payables930K1.99M(2.39M)0(11.44M)
Other Working Capital18.62M9.16M(35.28M)14.62M(11.87M)
Other Non-Cash Items139.74M(10.5M)(17.19M)(25.62M)(1.65M)
Operating Cash Flow(74.41M)(229.49M)(300.32M)(249.11M)(235.46M)
Capital Expenditures(3.47M)(9.06M)(4.13M)(2.02M)(410K)
Acquisitions (Net)(25.3M)179.68M000
Purchases of Investments(980.67M)(535.42M)(385.54M)(650.63M)(122.97M)
Sales of Investments529.92M355.74M647.3M611.56M316.18M
Other Investing Activities0(179.68M)000
Investing Cash Flow(479.51M)(188.75M)257.63M(41.08M)192.8M
Debt Repayment00000
Common Stock Issued382.21M284.74M30.28M265.89M1.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.88M5.17M4.47M4.26M0
Financing Cash Flow388.09M289.91M34.75M270.15M1.6M
Effect of Forex Changes00000
Net Change in Cash(165.83M)(128.33M)(7.93M)(20.04M)(41.05M)
Free Cash Flow(77.88M)(238.55M)(304.44M)(251.13M)(235.87M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$276.5M
+ D&A$3.6M
+ Stock-Based Comp$62.4M
+ Deferred Tax$0
- Working Capital-$23.3M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$235.5M
- Capex-$410.0K
= Free Cash Flow-$235.9M

Analysis

FY2025 free cash flow is -$235.9M. FCF conversion is 85.3% of net income. Operating cash flow was -$235.5M, with capex of -$410.0K. The largest bridge item is Stock-Based Comp at $62.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

Does RLAY generate free cash flow?

Relay Therapeutics, Inc. (RLAY) generated -$235.87M of free cash flow in fiscal 2025.

How much operating cash flow does RLAY produce?

Operating cash flow was -$235.46M, before capital expenditures of $410,000.00.